Statins decrease all-cause mortality only in CKD patients not requiring dialysis therapy-A meta-analysis of 11 randomized controlled trials involving 21,295 participants
Statins decrease all-cause mortality only in CKD patients not requiring dialysis therapy-A meta-analysis of 11 randomized controlled trials involving 21,295 participants
复制标题
DOI：
10.1016/j.phrs.2013.03.007
复制
发表时间：
2013-06-01
影响因子：
9.3
通讯作者：
Banach, Maciej
中科院分区：
文献类型：
--
作者：
Barylski, Marcin;Nikfar, Shekoufeh;Banach, Maciej
现有的研究报道了他汀类药物对慢性肾脏疾病（CKD）患者全因死亡率和心血管死亡率的益处。然而，对终末期肾病患者进行透析的研究得出了相互矛盾的结果。因此，我们进行了一项荟萃分析，并提供了迄今为止他汀类药物治疗对CKD患者心血管事件和全因死亡的影响的最可靠的试验数据。检索了1966年至2012年10月PubMed、Web of Science、Cochrane Library和Scopus的数据。最终的荟萃分析包括11项随机对照试验，涉及21,295名CKD患者。其中6857人接受透析治疗。非透析依赖型CKD患者使用他汀类药物可显著降低各种原因导致的死亡（相对危险度[RR]: 0.66； 95%可信区间[CI]: 0.55-0.79; p 0.05），但也可降低心脏原因导致的死亡(RR: 0.79; 95%CI: 0.64-0.98; p
The available studies have reported the benefits of statins on all-cause and cardiovascular mortality in chronic kidney disease (CKD) patients. However studies in end-stage renal disease patients on dialysis yielded conflicting results. Therefore, we performed a meta-analysis and provide the most reliable trial data to date on the impact of statin therapy on cardiovascular events and death from all causes in CKD patients. Data from PubMed, Web of Science, Cochrane Library, and Scopus for the years 1966 to October 2012 were searched. The final meta-analysis included 11 randomized controlled trials involving 21,295 participants with CKD. Among them 6857 were on dialysis. The use of statins in subjects with non-dialysis-dependent CKD resulted in a marked reduction in death from all causes (relative risk [RR]: 0.66; 95% confidence interval [CI]: 0.55-0.79; p 0.05), but had the effect of reducing death from cardiac causes (RR: 0.79; 95%CI: 0.64-0.98; p